The upregulation of microRNA-223 promoted the apoptosis of liver cancer cells via TLR4

References

• Bagheri A, Khorram Khorshid HR, Mowla SJ, Mohebbi HA, Mohammadian A, Yaseri M, Solaymani-Dodaran M, Sherafatian M, Tavallaie M. 2017. Altered miR-223 expression in sputum for diagnosis of non-small cell lung cancer. Avicenna J Med Biotechnol. 9(4):189–195.
   PubMedGoogle Scholar
• Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Bisceglie AMD, Ray RB. 2016. Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma. Am J Pathol. 186(2):242–247. doi: https://doi.org/10.1016/j.ajpath.2015.10.003
   Google Scholar
• Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, Wilson AE, Lewis DH, Padia SA. 2018. Prospective trial using internal pair-production positron emission tomography to establish the Yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. S0360301618302499.
   Google Scholar
• Dong X, Sui C, Huang K, Wang L, Hu D, Xiong T, Wang R, Zhang H. 2016. MicroRNA-223-3p suppresses leukemia inhibitory factor expression and pinopodes formation during embryo implantation in mice. Am J Transl Res. 8(2):1155–1163.
   PubMed Web of Science ®Google Scholar
• Dong Y-Q, Lu C-W, Zhang L, Yang J, Hameed W, Chen W. 2015. Toll-like receptor 4 signaling promotes invasion of hepatocellular carcinoma cells through MKK4/JNK pathway. Mol Immunol. 68(2 Pt C):671–683. doi: https://doi.org/10.1016/j.molimm.2015.10.015
   Google Scholar
• Farber BA, Lalazar G, Simon EP, Hammond WJ, Requena D, Bhanot UK, La Quaglia MP, Simon SM. 2018. Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget. 9(12):10211–10227. doi: https://doi.org/10.18632/oncotarget.23325
   PubMedGoogle Scholar
• Gu J, Sun R, Shen S, Yu Z. 2015. The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer. Onco Targets Ther. 8:2215–2225.
   PubMed Web of Science ®Google Scholar
• Hou HR, Kang Y, Li YK, Zeng YL, Wei JF, Ding GG, Peng Z, Shang J. 2017. Hepatitis B core antigen promotes invasion of hepatocellular carcinoma cell line HepG2.2.15 via Toll-like receptor 4. Zhonghua Gan Zang Bing Za Zhi. 25(12):908–913.
   Google Scholar
• Huang Y, Zhang Y, Ge L, Lin Y, Kwok HF. 2018. The roles of protein tyrosine phosphatases in hepatocellular carcinoma. Cancers (Basel). 10:3.
   Web of Science ®Google Scholar
• Imura S, Yamada S, Saito YU, Iwahashi S, Arakawa Y, Ikemoto T, Morine Y, Utsunomiya T, Shimada M. 2017. miR-223 and stathmin-1 expression in non-tumor liver tissue of patients with hepatocellular carcinoma. Anticancer Res. 37(10):5877–5883.
   Web of Science ®Google Scholar
• Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R, Huang XJG. 2018. MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. S0378111918302749.
   Google Scholar
• Kim HY, Lee DH, Lee J-H, Cho YY, Cho EJ, Yu SJ, Kim YJ, Yoon J-H. 2018. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer. 18(1):307. doi: https://doi.org/10.1186/s12885-018-4211-2
   Google Scholar
• Lee J, Kim CJ, Kim JS, Lee DC, Ahn S, Yoon BH. 2018. Increased miR-223 expression in foetal organs is a signature of acute chorioamnionitis with systemic consequences. J Cell Mol Med. 22(2):1179–1189.
   Web of Science ®Google Scholar
• Liu Y-C, Mao Y-Z, Wang J-C, Wang J, Lao X-M, Chen M-S, Li S-P. 2018. Hepatocellular carcinoma with en bloc diaphragmatic resection: A single-center experience over 14 years. Int J Surg. 53:93–97. doi: https://doi.org/10.1016/j.ijsu.2018.03.033
   Google Scholar
• Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng L, Shi Y, Wang H, Yin B, Xia J, et al. 2015. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget. 6(3):1740–1749. doi: https://doi.org/10.18632/oncotarget.2714
   Google Scholar
• Mirzaei HR, Sahebkar A, Mohammadi M, Yari R, Salehi H, Jafari MH, Namdar A, Khabazian E, Jaafari MR, Mirzaei H. 2016. Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des. 22(34):5257–5269. doi: https://doi.org/10.2174/1381612822666160303110838
   PubMed Web of Science ®Google Scholar
• Miura K, Ishioka M, Minami S, Horie Y, Ohshima S, Goto T, Ohnishi H. 2016. Toll-like receptor 4 on macrophage promotes the development of steatohepatitis-related hepatocellular carcinoma in mice. J Biol Chem. 291(22):11504–11517. doi: https://doi.org/10.1074/jbc.M115.709048
   Google Scholar
• Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, Chen Z, Chen F, Wang D. 2013. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett. 6(2):359–366. doi: https://doi.org/10.3892/ol.2013.1375
   PubMed Web of Science ®Google Scholar
• Nirei K, Kanda T, Nakamura H, Matsuoka S, Takayama T, Sugitani M, Moriyama M. 2018. Persistent hepatic inflammation plays a role in hepatocellular carcinoma after sustained virological response in patients with HCV infection. Int J Med Sci. 15(5):466–474. doi: https://doi.org/10.7150/ijms.23147
   Google Scholar
• Pomari E, Lovisa F, Carraro E, Primerano S, D'Amore ESG, Bonvini P, Nigro LL, Vito R, Vinti L, Farruggia P, et al. 2017. Clinical impact of miR-223 expression in pediatric T-cell lymphoblastic lymphoma. Oncotarget. 8(64):107886–107898. doi: https://doi.org/10.18632/oncotarget.22386
   Google Scholar
• Qin Y, Ye J, Wang P, Gao L, Wang S, Shen H. 2016. miR-223 contributes to the AGE-promoted apoptosis via down-regulating insulin-like growth factor 1 receptor in osteoblasts. Biosci Rep. 36(2):e00314. doi: https://doi.org/10.1042/BSR20150271
   Google Scholar
• Ruan P, Yang C, Su J, Ou C, Cao J, Luo C, Tang Y, Qin H, Sun W, Li Y. 2014. Expressions and significance of TLR2 and TLR4 in Kupffer cells of tree shrews chronically infected with hepatitis B virus. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 30(7):686–690.
   Google Scholar
• Sepehri Z, Kiani Z, Kohan F, Alavian SM, Ghavami S. 2017. Toll like receptor 4 and hepatocellular carcinoma; A systematic review. Life Sci. 179:80–87. doi: https://doi.org/10.1016/j.lfs.2017.04.025
   PubMed Web of Science ®Google Scholar
• Sugawara S, Yamada Y, Arai T, Okato A, Idichi T, Kato M, Koshizuka K, Ichikawa T, Seki N. 2018. Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis. J Hum Genet. 63(5):657–668. doi: https://doi.org/10.1038/s10038-018-0437-8
   Google Scholar
• Tang Y, Wang Y, Chen Q, Qiu N, Zhao Y, You X. 2015. MiR-223 inhibited cell metastasis of human cervical cancer by modulating epithelial-mesenchymal transition. Int J Clin Exp Pathol. 8(9):11224–11229.
   PubMed Web of Science ®Google Scholar
• Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, et al. 2018. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett. 15(4):4411–4422.
   Web of Science ®Google Scholar
• Wang L, Zhu R, Huang Z, Li H, Zhu H. 2013. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci. 58(8):2223–2236. doi: https://doi.org/10.1007/s10620-013-2745-3
   PubMed Web of Science ®Google Scholar
• Wang S, Kalim M, Liang K, Zhan J. 2018. Polyclonal antibody production against rGPC3 and their application in diagnosis of hepatocellular carcinoma. Prep Biochem Biotechnol. 48(5):435–445. doi: https://doi.org/10.1080/10826068.2018.1452258
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai J, Zeng X, Chen Y, Yan W, Ouyang Y, Xiao D, Zeng Z, Huang L, Liu A. 2015. Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling. BMC Cancer. 15:821. doi: https://doi.org/10.1186/s12885-015-1866-9
   PubMed Web of Science ®Google Scholar
• Wu ZF, Zhou XH, Hu YW, Zhou LY, Gao YB, Peng XH, Yang XH, Zhang JY, Hu Y, Zeng ZC. 2014. TLR4-dependant immune response, but not hepatitis B virus reactivation, is important in radiation-induced liver disease of liver cancer radiotherapy. Cancer Immunol Immunother. 63(3):235–245. doi: https://doi.org/10.1007/s00262-013-1504-9
   Google Scholar
• Xu JH, Chang WH, Fu HW, Yuan T, Chen P. 2018. The mRNA, miRNA and lncRNA networks in hepatocellular carcinoma: an integrative transcriptomic analysis from gene expression omnibus. Mol Med Rep. 17(5):6472–6482.
   PubMed Web of Science ®Google Scholar
• Yin Y, Li F, Li S, Cai J, Shi J, Jiang Y. 2017. TLR4 influences hepatitis B virus related hepatocellular carcinoma by regulating the Wnt/beta-Catenin pathway. Cell Physiol Biochem. 42(2):469–479. doi: https://doi.org/10.1159/000477594
   Google Scholar
• Zhang W, Qian S, Yang G, Zhu L, Zhou B, Wang J, Liu R, Yan Z, Qu X. 2018. MicroRNA-199 suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma. Gene. 659:22–28. doi: https://doi.org/10.1016/j.gene.2018.03.053
   PubMed Web of Science ®Google Scholar
• Zhao FY, Han J, Chen XW, Wang J, Wang XD, Sun JG, Chen ZT. 2016. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med. 38(1):183–191. doi: https://doi.org/10.3892/ijmm.2016.2588
   Google Scholar
• Zhao H, Wu M, Zhu L, Tian Y, Wu M, Li Y, Deng L, Jiang W, Shen W, Wang Z, et al. 2018. Cell-penetrating peptide-modified targeted drug-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound for precision theranostics against hepatocellular carcinoma. Theranostics. 8(7):1892–1910. doi: https://doi.org/10.7150/thno.22386
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhu N, Wang X, Wang L, Gu LJ, Yuan WJ. 2013. The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis. Arch Virol. 158(2):425–433. doi: https://doi.org/10.1007/s00705-012-1508-3
   Google Scholar